Live Status Check

NCT04787042 Recruiting Status

Real-time enrollment status for this i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. clinical trial

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Checked: March 2, 2026 at 8:49 AM UTC

NCT04787042 Status Summary

NCT NumberNCT04787042
Recruiting StatusRecruiting
ConditionI cannot determine the primary medical condition from the provided information. The study title only mentions "ST-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (ST-067, Obinutuzumab, and pembrolizumab) rather than medical conditions. The brief summary field appears to be incomplete. Without information about the actual disease or condition being treated, I cannot extract a patient-facing medical condition.
PhaseClinical Trial
Target Enrollment316 participants
Active Locations6 sites in the US
SponsorSimcha IL-18, Inc.
Last Updated on CT.govNovember 15, 2024 (Nov 15, 2024)

About NCT04787042 Enrollment Status

As of March 2, 2026: Clinical trial NCT04787042 is currently recruiting participants. This clinical trial study for i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. is actively seeking new participants at 6 locations across the United States. The study is sponsored by Simcha IL-18, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.

Frequently Asked Questions About NCT04787042

Is NCT04787042 still recruiting?

Yes, NCT04787042 is actively recruiting participants as of March 2, 2026. You can check eligibility and apply through HelloStudys.

Where is NCT04787042 recruiting?

This trial is recruiting at 6 locations in the United States. View all available locations on the full study page.

How do I enroll in NCT04787042?

Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.

When was NCT04787042 status last updated?

The official ClinicalTrials.gov record for NCT04787042 was last updated Nov 15, 2024 (November 15, 2024). HelloStudys verifies this status automatically.

Browse More I cannot determine the primary medical condition from the provided information. The study title only mentions "ST-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (ST-067, Obinutuzumab, and pembrolizumab) rather than medical conditions. The brief summary field appears to be incomplete. Without information about the actual disease or condition being treated, I cannot extract a patient-facing medical condition. Trials

Ready to Apply?

Check your eligibility for this clinical trial